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Effect of patient’s sex on risk of recurrent venous thromboembolism: A
meta-analysis
McRae S, Tran H, Schulman S, et al. Lancet 2006;368:371-78.
Conclusion: Men have a 50% higher risk of recurrent venous throm-
boembolism (VTE) after cessation of anticoagulant therapy.
Summary: The authors performed a meta-analysis to examine the
question of risk of recurrent VTE in men versus women after cessation of
anticoagulation treatment. Eligible articles were identified using the Coch-
ran Database 2005, Issue 1, EM (1980 to February 2005) and MedLine
(Source Pub Med, 1996 to February 2005). To be included, a trial must
have been prospective and randomized. Patients were required to have
objectively diagnosed VTE. Treatment must have been for a minimum of 1
month, and there must have been follow-up for recurrence of VTE after
anticoagulant therapy was stopped. The authors analyzed study design,
study quality, and the sex, number, and age of enrolled patients as well as risk
factors for VTE. The treatment given, duration of followup, and number of
episodes of recurrent VTE was also analyzed.
Based on the data, the estimate of relative risk of recurrent VTE formen
compared with women was 1.6 (95% confidence interval [CI], 1.2 to 2.0).
The higher risk of recurrent VTE in males was consistent across predefined
subgroups. There was a higher risk of recurrence in males from observational
studies (relative risk 2.1; 95% CI 1.5 to 2.9) than in randomized trials
(relative risk 1.3; 95% CI, 1.0 to 1.8). A reduced rate of recurrence of VTE
in women after VTE associated with pregnancy or estrogen therapy did not
account for the differences between men and women.
Comment: This meta-analysis used strict inclusion criteria for studies
and analyzed large numbers of patients with predefined subgroups for
analysis. This lends strength to the authors’ conclusions. There was, how-
ever, heterogenicity among studies and differences among relative risks from
randomized trials vs observational studies. The trials did not have individual
patient data, and, therefore, a true multivariant analysis could not be done to
assess individual variables on study outcome. Nevertheless, the data argue
strongly for inclusion of sex as another variable in determining the length of
anticoagulant therapy following VTE.
Angiotensin-converting enzyme inhibitors and aortic rupture: A
population-based, case-controlled study
Hackam DJ, Thiruchelvam D, Redelmeier DA. Lancet 2006; 368:659-65.
Conclusion: Angiotensin-converting enzyme (ACE) inhibitors appear
to be associated with a reduced risk of ruptured abdominal aortic aneurysm
(AAA).
Summary: Studies in animal models indicate ACE inhibitors may
prevent expansion and rupture of aortic aneurysms. In this investigation,
ruptured AAA in humans was studied for association with ACE inhibitors.
This was a population-based, case-controlled study from April 1, 1992, to
April 1, 2002, using linked administrative databases from Ontario, Canada.
The study sample was 15,326 consecutive patients 65 years of age who
were admitted to a hospital with either intact or ruptured AAA as the primary
diagnosis.
Patients receiving ACE inhibitors before admission were less likely to
present with ruptured AAA (odds ratio [OR], 0.82; 95% confidence interval
[CI], 0.74 to 0.97) compared with those who did not receive ACE inhibi-
tors. Multiple adjustments, including those for demographic characteristics,
comorbidities, risk factors for rupture, measures of health care use, contra
indications to ACE inhibitors, and aneurysm screening yielded similar results
(OR, 0.83; 95% CI, 0.73 to 0.95). Similar findings were noted in subgroups
at high risk for rupture, including hypertensive patients and those patients
75 years of age. No protective associations were noted with other antihy-
pertensive medications including -blockers (OR, 1.02; 95% CI, 0.89 to
1.17), -blockers (OR, 1.15; 95% CI, 0.86 to 1.54), angiotensin receptor
blockers (OR, 1.24; 95% CI, 0.71 to 2.18), calcium channel blockers (OR,
1.01, 95%CI 0.89 to 1.14), or thiazide diuretics (OR, 0.91; 95%CI, 0.78 to
1.07).
Comment: The study has several important limitations. Healthier
patients, perhaps with a lower risk of rupture, may have been more likely to
receive ACE inhibitors. Of most importance is that the authors did not
control for AAA size, and certainly diameter is a significant predictor of AAA
rupture. In addition, AAAs grow for a long period of time, and no analysis
was done for the length of time the patients were on ACE inhibitors. The
data are interesting but insufficient to recommend routine treatment of AAA
patients with ACE inhibitors at this time.
30 day results from the SPACE trial of stent-protected angioplasty
versus carotid endarterectomy in symptomatic patients: A randomised
non-inferiority trial
The SPACE Collaborative Group. Lancet 2006;368:1239-47.
Conclusion: Short-term results do not support widespread use of
carotid artery stenting for treatment of symptomatic carotid artery stenosis.
Summary: This was a prospective, randomized clinical trial from 35
centers conducted in German, Austria, and Switzerland in which 1200
patients with symptomatic carotid artery stenosis were randomly assigned to
receive either carotid artery stenting (n  605) or carotid endarterectomy
(n 595). Ipsilateral ischemic stroke or death from the time of randomiza-
tion to 30 days after the procedure were primary end points for the study.
The noninferiority margin was defined as2.5%, and this was on the basis of
an expected event rate of 5%. An intention-to-treat analysis was used.
The study analyzed 1183 patients. The primary end point was achieved
in 6.84% in patients treated with carotid artery stents, and 6.34% in patients
treated with carotid endarterectomy, an absolute difference of 0.51% (95%
confidence interval [CI] 1.89% to 2.91%). In determining noninferiority,
the one-sided P value for noninferiority was 0.09. If only patients treated per
protocol were analyzed, and the 72 patients who were not treated, changed
treatment groups, or were treated 14 days after randomization were
excluded, the final outcome event rate was 6.95% in the carotid artery
stenting group and 5.64% in the carotid endarterectomy group (absolute
difference 1.32%, 95% CI 1.1% to 3.76%).
Comment: The study was unable to prove carotid stenting was not
inferior to carotid endarterectomy. The study does not prove that carotid
artery stenting is inferior to carotid endarterectomy. However, for all out-
come analyses, there appeared to be a tendency towards better results with
endarterectomy. The author’s conclusion that “the results of this trial (do)
not justify the widespread use of carotid artery stenting for treatment of
carotid artery stenosis”, is consistent with the recently published French trial
in the New England Journal of Medicine. In that trial, carotid stenting was
inferior to carotid endarterectomy in patients of symptomatic carotid steno-
sis. The results of the SPACE trial are also consistent with two large recently
published meta-analyses (Stroke 2005;36:905-11 and Neurosurgery 2005;
56:1171-79).
Identification of patients at low risk for recurrent venous thromboem-
bolism by measuring thrombin generation
Hron G, Kollars N, Binder BR. JAMA 2006;296:397-402.
Conclusion: Patients at low risk for recurrent venous thromboembo-
lism (VTE) can be identified by measurement of thrombin generation.
Summary: Patients with VTE are often investigated for thrombophilia
risk factors. A large number of potential thrombophilia risk factors make this
investigation complex and expensive. The authors sought to determine
whether the risk of recurrent VTE could be assessed by a global coagulation
assay that measures thrombin generation.
This was a cross-sectional, prospective cohort study of 914 patients. All
patients had a spontaneous VTE. They were followed up for average of 47
months after discontinuation of oral anticoagulant therapy. The study
period was from July 1992 to July 2005. A commercially available assay
system was used to determine thrombin generation. Excluded patients
included those with secondary VTE, those with recurrent VTE, or those
with a known thrombophilia risk factor such as antithrombin III, protein C
or protein S deficiencies, or the presence of lupus anticoagulant, cancer, or
pregnancy. The primary outcome measure was an objectively documented
episode of recurrent VTE.
VTE recurred in 100 patients (11%). Patients without recurrent VTE
generated less thrombin than those with recurrent VTE (349.2 108 nN vs
415  110.5 nN, P  .001). In patients with thrombin generation values
between 400 nN and 300 nN, the relative risk of recurrence compared to
patients with thrombin generations 400 nN was 0.42 (95% confidence
interval [CI], 0.26 to 0.67, P .001). In patients with measured thrombin
generations 300nN, relative risk was 0.37 (95% CI, 0.21 to 0.66, P 
.001). Over 4 years, the probability of VTE recurrence in patients with
thrombin generation 400 nN was 6.5% (95% CI, 4.0% to 8.9%). In those
patients with thrombin generation values 400, the probability of VTE
recurrence was 20.0% (95% CI, 14.9% to 25.1%, P  .001). Patients with
thrombin generation 400 nN had a 60% lower recurrence of VTE than
those with greater values of thrombin generation (relative risk, 0.40; 95%CI,
0.27 to 0.60, P  .001.
Comment:There are data to suggest that patients with idiopathic VTE
benefit from longer periods of anticoagulation than those with VTE and a
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recognizable risk factor such as surgery or trauma. Given the risks of
long-term anticoagulant, it is desirable to identify which patients with
idiopathic VTE are particularly prone to recurrence. If this study can be
confirmed by others, measurement of thrombin generation may prove to be
a relatively simple method of stratifying patients for length of anticoagula-
tion after a first time episode of idiopathic VTE.
The examination assessment of technical competence in vascular surgery
Pandey DA, Wolfe JHN, Liapis CD; and the European Board of Vascular
Surgery. Br J Surg 2006;93:1132-8.
Conclusion: It is possible to develop a model to assess surgical tech-
nical skills in an examination setting.
Summary: The European Board of Surgery Qualifications in Vascular
Surgery examination is a Pan European examination for vascular surgeons
who have certificates of competence from their home country. The authors
sought to evaluate the inclusion of technical skills as a component of the
European Board of Surgery Qualifications in Vascular Surgery Examination.
Evaluated were 30 vascular surgeons, including 22 candidates for
certification, and 8 examiners. Each was tested on dexterity and ability to
perform a vascular anastomosis and dissection pertinent to a vascular proce-
dure. Dissection was tested on a synthetic saphenofemoral junction model.
The ability to perform an anastomosis was assessed using an anterior tibial
artery of a synthetic leg model. Dexterity was tested using a knot-tying
simulator with electromagnetic motion analysis. Validated rating scores were
used by two independent examiners for each area. The technical points of
the examination were weighted as listed: 35% for dissection, 45% for anas-
tomotic competence, and 20% for dexterity.
Examiners performed better than the candidates for certification with
respect to dissection (P .001) anastomosis (P .002) and dexterity (P
.005). No correlation was observed between technical skills tested by this
examination and scores on the oral certifying examination.
Comment: The authors point out that it seems silly not to assess
technical skills in a certifying examination for a surgeon. Nevertheless, it is
extremely unusual for technical skills to be assessed in a national certifying
surgical examination. Before implementing this type of assessment, it seems
prudent to correlate results of scores from this examination with established
surgeons’ morbidity and mortality rates, as well as rates of technical error in
day-to-day practice. I know of no movement to incorporate a technical skills
examination into the current North American certifying examination for
vascular surgery.
Cloning the arterial IgA antibody response during acute
Kawasaki disease
Rowley AH, Shulman ST, Garcia FL, et al. J Immunol 2005;175:8386-91.
Conclusion: The arterial antibody response in human vasculitis can be
cloned and used to determine antigenic targets of antibodies produced by
plasma cells in inflamed vascular tissue.
Summary: In children from developed nations, Kawasaki disease is the
most common acquired cardiac disease. It is a form of vasculitis. The
etiology is unknown, but may be a microbial agent. In Kawasaki disease,
oligoclonal immunoglobulin (Ig) A plasma cells infiltrate inflamed tissues,
including coronary arteries. Antibodies with an -H chain sequence are preva-
lent in acute Kawasaki disease. These antibodies can be manufactured and then
used to detect antigen in coronary arteries of patients with Kawasaki disease.
These antigens appear to be localized to cytoplasmic inclusion bodies.
The authors synthesized 13monoclonal antibodies using combinations
of -H and -L chain sequences. They then tested the binding of these
antibodies to tissue afflicted by acute Kawasaki disease. The synthetic mono-
clonal antibodies detected antigen in cytoplasmic inclusion bodies in acute
Kawasaki disease tissue. The strength of the binding of the antibodies to the
acute Kawasaki disease tissue was roughly parallel to the -sequences prev-
alent in the Kawasaki disease tissue. Antibodies made from two prevalent
-H chains bound more strongly to acute Kawasaki disease tissues than did
antibodies made from less prevalent -chains. All synthetic antibodies that
detected antigen in the acute Kawasaki disease tissues had the same binding
pattern.
Comment: This is highly sophisticated immunology. The details of
the paper are certainly beyond the knowledge base of most vascular
surgeons. However, the concept presented here is extremely interesting
in that the synthetic antibodies bound to cytoplasmic inclusion bodies in
a similar pattern. That result is consistent with the presence of a microbial
pathogen. It suggests an infectious etiology for at least this form of
vasculitis.
Physical activity during daily life and mortality in patients with periph-
eral arterial disease
Garg PK, Tian L, Criqui MH, et al. Circulation 2006;114:242-8.
Conclusion: Controlling for confounding variables, including ankle
brachial index (ABI) and body mass index (BMI), patients with peripheral
arterial disease (PAD) and higher levels of physical activity have reduced
cardiovascular events and mortality compared with those with PAD and
lower levels of physical activity.
Summary: The authors investigated the effect of physical activity on
cardiovascular events and mortality in patients with PAD. There were 460
men and women with PAD (mean age, 71.9 8.4 years) who were followed
up for 57 months (interquartile range, 36.6 to 61.9 months). Vertical
accelerometers were used to measure physical activity in 225 patients con-
tinuously for 7 days. Analysis for mortality and cardiovascular events with
respect to level of physical activity was adjusted for body mass index, age,
race, sex, lipid levels, comorbidities, smoking, hypertension, leg symptoms,
and ankle-brachial index.
At 57-month follow-up, 29% of the patients (n  134) had died,
including 75 patients who wore accelerometers. As measured by vertical
accelerometer, higher baseline physical activity levels were associated with
lower all cause mortality (Ptrend  .003). Patients in the lowest quartile of
physical activity as measured by accelerometer had higher total mortality
compared with those in the highest quartile of accelerometer-measured
physical activity (hazard ratio, 3.48, 95% confidence interval [CI], 1.23 to
9.87, P  .019). Combining cardiovascular events and cardiovascular mor-
tality provided similar results (Ptrend  .005). Increasing numbers of stair
flights climbed during a one week period were also associated with lower
total mortality (Ptrend  .035).
Comment: It is well known that higher physical activity levels are
associated with lower all-cause and cardiovascular disease mortality in
healthy populations. It appears this is also the case in patients with PAD.
Therefore, even if a walking program does not improve a patient’s claudica-
tion distance, it may be that patients should still be encouraged to increase
their physical activity levels to prolong survival and decrease adverse cardio-
vascular events.
Underinvestigation and undertreatment of carotid disease in elderly
patients with transit ischemic attack and stroke: Comparative
population-base study
Fairhead JF, Rothwell PM. BMJ 2006;333:525-7.
Conclusions: There is an increase in incidence of symptomatic carotid
stenosis with age. Patients 80 years of age with transit ischemic attack
(TIA) or ischemic stroke are poorly evaluated.
Summary: This was a comparative population-base study designed to
assess for under-investigation of older patients who have TIAs or stroke. The
authors used data from routine clinical practice from Oxfordshire, England
and compared it with data obtained from the Oxford Vascular Study
(OXVASC), a nested population study of the incidence of TIAs and stroke in
the same area.
Patients were identified who underwent carotid imaging for ischemic
retinal or cerebral transient ischemic attacks or stroke from April 1, 2002, to
March 31, 2005, in the Oxford Vascular Study, and from April 1, 2002, to
March 31, 2003, in routine clinical practice. Age-specific rates were deter-
mined for carotid imaging, diagnosis of50% symptomatic carotid stenosis,
and use of carotid endarterectomy in patients who had had a recent transit
ischemic attack or stroke.
The incidence of 50% symptomatic internal carotid artery (ICA)
stenosis increased significantly with age. It was frequently diagnosed in
patients aged 80 years. The rates of carotid imaging, diagnosis of 50%
symptomatic stenosis, and performance of carotid endarterectomy were all
substantially lower in patients 80 years in routine practice compared with
the Oxford Vascular Study (carotid imaging: relative rate 0.36, 95% confi-
dence interval [CI], 0.8 to 0.46, P .001; for diagnosis of50% symptom-
atic stenosis, 0.33, 95% CI, 0.16 to 0.69, P  .004; and carotid endarter-
ectomy, 0.19; 95% CI 0.06 to 0.63, P  .007).
Comment: The data indicate that although rates of symptomatic
carotid stenosis increase steeply with age, most patients 80 who have
symptomatic carotid stenosis are poorly investigated in routine clinical
practice. Because rates of endarterectomy increase steeply in the patients
80 years of age in the Oxford Vascular Study, the low investigation rates of
symptomatic patients 80 in routine clinical practice indicates that this is
not likely due to contraindications to treatment or to patient choice. It may
be that practitioners have a bias against treatment of elderly patients with
transit ischemic attacks or stroke, or a knowledge deficit exists among
practitioners in routine practice regarding the risk of carotid endarterectomy
in elderly patients.
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